reported the outcomes of a retrospective cohort of patients from the Alberta Immunotherapy Database in a RW population with NSCLC and PD-L1 TPS ≥ 50% treated with first-line Pembrolizumab [83]. Here, CD274 is linked to non-small cell lung carcinoma.